Corrects first Overview bullet to say revenue increased, not declined, year over year
Overview
US biopharma developer's Q4 revenue increased yr/yr, net loss widened to $47.2 mln
Company implemented reduction in force to align resources with near-term priorities
Outlook
Company expects current cash to fund operations into Q1 2027
Result Drivers
PROSERA TRIAL OUTCOME - Company said Q4 results and near-term focus were shaped by the Phase 3 PROSERA trial, which did not meet its primary endpoint and prompted further data analysis and regulatory engagement
Cash, cash equivalents and marketable securities as of December 31, 2025, were $136.9 million
COST CONTAINMENT - Company implemented a reduction in force and other cost-containment measures to align resources with near-term priorities
Company press release: ID:nBw6N1yfFa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 EPS | -$0.21 | ||
Q4 Net Income | -$47.24 mln | ||
Q4 Basic EPS | -$0.21 | ||
Q4 Operating Expenses | $59.84 mln | ||
Q4 Operating Income | -$46.04 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Gossamer Bio Inc is $2.00, about 338.6% above its March 16 closing price of $0.46
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)